China's Companion Animal Health Market 2019-2024 - The Increase in Pet Adoption, Mostly by Nuclear Families, is a Key Driver -

The "China Companion Animal Health Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

Retrieved on: 
Thursday, May 23, 2019 - 10:14am

The "China
Companion Animal Health Market - Growth, Trends, and Forecast (2019 -
report has been added to's

The Chinese companion health market is growing, due to the factors, like
the rising popularity of pet ownership in China and the introduction of
healthcare innovations converging with different therapeutic indications.

According to the National Bureau of Statistics of China, it has been
estimated that China is the third-largest country, in terms of dog
ownership, a total of 27.4 million pet dogs, standing behind the United
States and Brazil, with 55.3 million and 35.7 million dogs,
respectively. China also stands second in the ownership of pet cats
(58.1 million).

With the increase in the number of companion animals, owners are
becoming increasingly aware of their pet's health and nutrition, and are
also seeking veterinary services. This, in turn, is creating a growing
demand for diversified forms of companion animal healthcare products.

Vaccines Contributed the Largest Share, in Terms of Revenue,
in the Therapeutics Segment

The three major types of vaccines available for companion animals are
inactivated (killed) vaccines (which contain bacteria and virus that
have been grown in cultures and then killed by heating or chemical
treatments), live attenuated vaccines (which contain live viruses or
bacteria that have been severely weakened), and subunit vaccines (which
contain viral or bacterial antigens that can trigger an immune response).

In 2017, more than 3,500 cats and dogs were cured from various diseases
in China through animal welfare programs, funded by the Animals Asia
Foundation. The animals were cured and vaccinated efficiently, thus
protecting their health and saving their life.

Competitive Landscape

Leading global companies are partnering with the Chinese companies for
their distribution in the country. For instance, Meili Omni-Honesty is a
joint venture between Boehringer Ingelheim, a leading global
pharmaceutical company and the world's second-largest animal health
company, Beijing KangMu Omni-Honesty Animal Health Products Co. Ltd.

Key market players in the market include Bayer AG, China Animal
Husbandry Co. Ltd, Dachang, Elanco Animal Health, Merck & Co.,
Vetoquinol SA, Virbac, and Zoetis Inc., among others.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increase in Pet Adoption, Mostly by Nuclear Families

4.2.2 Increasing in Initiatives by the Governments & Animal Welfare

4.2.3 Advanced Technology in Animal Healthcare

4.3 Market Restraints

4.3.1 Use of Counterfeit Medicines

4.3.2 Increasing Costs of Animal Testing and Veterinary Care

4.4 Porter's Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 By Products

5.1.1 Therapeutics Vaccines Parasiticides Anti-Infectives Medicinal Feed Additives Other Therapeutics

5.1.2 Diagnostics Immunodiagnostic Tests Molecular Diagnostics Diagnostic Imaging Other Diagnostics

5.2 By Animal Type

5.2.1 Dogs and Cats

5.2.2 Horses

5.2.3 Other Companion Animals


6.1 Company Profiles

6.1.1 Bayer AG

6.1.2 China Animal Husbandry Co. Ltd.

6.1.3 Dachang

6.1.4 Elanco Animal Health

6.1.5 Merck & Co.

6.1.6 Vetoquinol S.A.

6.1.7 Virbac

6.1.8 Zoetis Inc.


For more information about this report visit